Advanced Prostate

Hormone Naive

- Non-Metastatic
  - IRB # 11268: Salvage radiation + enzalutamide/placebo for recurrent prostate cancer

Metastatic

- Non-Metastatic
  - IRB# 9892: Phase III study comparing ADT + Bicalutamide to ADT + TAK-700

Incomplete Response to Hormone Therapy

- Non-Metastatic
  - No Trials Currently Available

Castrate Resistant

- Non-Chemotherapy, No prior AR Targeting Agent
  - IRB# 9259: Phase II study involving enzalutamide and biopsy for research

- Non-Chemotherapy Post-AR Targeting Agent
  - IRB# 11025: Phase II study of pembrolizumab after progression on enzalutamide

- 1st Line Chemotherapy
  - IRB# 10479: Phase III study of docetaxel + dendritic cell vaccine or placebo

- Post-Chemotherapy
  - IRB# 16093: Phase II study of pembrolizumab in subjects previously treated with chemotherapy

- Supportive Care/Biomarker
  - IRB# 9204: Stand Up To Cancer Biopsy for research

Metastatic

- Hormone Naïve
  - IRB # 11268: Salvage radiation + enzalutamide/placebo for recurrent prostate cancer

- Non-Metastatic
  - IRB# 9892: Phase III study comparing ADT + Bicalutamide to ADT + TAK-700

- Incomplete Response to Hormone Therapy
  - No Trials Currently Available

- Castrate Resistant
  - Non-Chemotherapy, No prior AR Targeting Agent
    - IRB# 9259: Phase II study involving enzalutamide and biopsy for research

- Post-Chemotherapy
  - IRB# 10479: Phase III study of docetaxel + dendritic cell vaccine or placebo

- Supportive Care/Biomarker
  - IRB# 9204: Stand Up To Cancer Biopsy for research

New Trials Coming Soon

www.ohsu.com/cancer